Profitability
Weight: 25%
D+
42
- 5yr Avg ROIC 1.5%
- Operating Margin Trend +6.65 pp/yr
ANIP
ANI Pharmaceuticals, Inc.
AlphaQuality composite grade, weighted for platform & compounding fcf businesses.
⚠ 3 of the last 5 fiscal years showed negative net income — AlphaQuality will not grade above F for persistent unprofitability in a platform & compounding fcf business.
Grade overrides the 30.0 pillar composite — hard gates always win.
Capital Efficiency
Weight: 15%
F
6
- 5yr Avg ROE -0.4%
- 5yr Share-Count CAGR 13.9%
Growth Quality
Weight: 25%
A+
100
- 5yr Revenue CAGR 42.2%
- 5yr EPS CAGR 87.9%
- Revenue-Growth Years (5) 5/5
Cash Generation
Weight: 20%
C
56
- 5yr FCF Margin 4.6%
- 5yr FCF/NI Conversion 3.77x
Balance Sheet
Weight: 10%
B+
79
- Net Debt / EBITDA 0.19x
- Interest Coverage (EBIT/Int) 5.78x
- Altman Z-Score 2.74
Stability
Weight: 5%
C
51
- EPS Volatility (σ/μ) 0.83
- Piotroski F-Score 7
- Negative-Revenue Years (5) 0/5
Guru Flow
Curated superinvestor sentiment — not part of the AlphaQuality grade.3 of 4 gurus held; 1 added; 2 trimmed; 1 full exit.
- Holders
- 3 -1
- Avg Δ position
- -6.8%
- New buys
- 0
- Full exits
- 1
- Wood sold -100%
- Greenblatt decreased -27%
- Laffont increased +22%